Author

Gian Paolo Dagrada

Fondazione IRCCS Istituto Nazionale dei TumoriORCID 0000-0002-6743-1935Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Assay:ChIP-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Alessandro GronchiiD· 1 shared Alex KentsisiD· 1 shared Anna Maria FrezzaiD· 1 shared Cesare SoffientiniiD· 1 shared Elisa Savio· 1 shared Loredana ClerisiD· 1 shared Luca SigalottiiD· 1 shared Marta BarisellaiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alessandro GronchiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combination

Noemi Arrighetti, Cesare Soffientini, Valentina Zuco, Stefano Percio, Loredana Cleris, Suzan Abdulrazak Ahmed, Elisa Savio, Luca Sigalotti, Roberta Maestro, Silvia Brich, Gian Paolo Dagrada, Marta Barisella, Paola Collini, Alex Kentsis, Paul H. Huang, , Sandro Pasquali

This paper identifies HDAC inhibition as a strategy to overcome resistance to EZH2 inhibitors in INI1-deficient epithelioid sarcoma by restoring H3K27 acetylation and enhancing therapeutic response.

bioRxiv · Aug 4, 2026 · PreprintCancer Biology